Safety of oral itraconazole in the treatment of seborrheic dermatitis

Lubna Khondker, Md Abdul Wahab, Md Shirajul Islam Khan, Sonia Shirin


Background Seborrheic dermatitis (SD) is a chronic, papulosquamous dermatosis and Malassezia yeasts are considered as causative factors. The dual antifungal and anti-inflammatory effects of oral itraconazole account for its prolonged therapeutic action in SD.


Objectives: To assess the safety of oral itraconazole in the treatment of seborrheic dermatitis. 


Patients and methods During a period of total 2 years from January, 2008 to December, 2009, 37 patients of SD were treated with oral itraconazole (200 mg/day for 7 days) in first month and consecutive use of 200 mg/day for the first 2 days of the following 11 months. Patients were followed up monthly for clinical side effects and biochemical derangements.


Results 16 (43.2%) patients suffered from different side effects of drug i.e. nausea in 16 (76.2%) patients, followed by abdominal pain in 3 (14.3%) and diarrhea in 2 (9.5%). These were self-limiting and did not warrant discontinuation of therapy. Biochemical abnormalities were not seen in any patient.


Conclusion The study suggests that oral itraconazole is a safe treatment option of seborrheic dermatitis.



Itraconazole, seborrheic dermatitis, safety

Full Text:



Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA and Katz SI. Fitzpatrick’s Dermatology in General Medicine. 6th edition. Philadelphia: McGraw-Hill; 2003. P. 1198-1204.

James WD, Berger TG, Elston D. Andrews’ Diseases of the Skin-Clinical Dermatology, 10th edition. Philadelphia: Saunders Elsevier; 2006. P. 191-2.

Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18: 13-26.

Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV infected patients on highly active antiretroviral therapy. HIV Med 2004; 5: 50-4.

Kose O, Erbil H, Gur AR. Oral itraconazole for the treatment of seborrheic dermatitis: an open, non-comparative trial. J Eur Acad Dermatol Venereol 2008; 19: 172-5.

Baysal V, Yildirim M, Ozcanli C, Ceyhan M. Itraconazole for the treatment of seborrheic dermatitis: a new treatment modality. Int J Dermatol 2004; 43: 63-6.

Shemer A, Baruch Kaplan B, Nir Nathansohn N et al. Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study. Isr Med Assoc J 2008; 10: 417-8.


  • There are currently no refbacks.

ISSN: 1560-9014